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Abstract 
Background: The cardio-protective effects of flavonoids are still controversial; many studies referred to the benefits 
of specific foods, such as soy, cocoa, tea. A population-based cohort of middle-aged adults, coming from a semi-rural 
area where the consumption of those foods is almost negligible, was studied.
Aims: The primary objective was establishing if flavonoid intake was inversely associated with the cardiovascular (CV) 
risk evaluated after 12-year follow-up; the associations between flavonoid intake and CV incidence and mortality and 
all-cause mortality were also evaluated.
Methods: In 2001–2003, a cohort of 1,658 individuals completed a validated food-frequency questionnaire. Anthro-
pometric, laboratory measurements, medical history and the vital status were collected at baseline and during 2014. 
The CV risk was estimated with the Framingham risk score.
Results: Individuals with the lowest tertile of flavonoid intake showed a worse metabolic pattern and less healthy 
lifestyle habits. The 2014 CV risk score and the increase in the risk score from baseline were significantly higher with 
the lowest intake of total and all subclasses of flavonoids, but isoflavones, in a multiple regression model. During 
follow-up, 125 CV events and 220 deaths (84 of which due to CV causes) occurred. CV non-fatal events were less 
frequent in individuals with higher flavonoid intake (HR = 0.64; 95%CI 0.42–1.00 and HR = 0.46; 95%CI 0.28–0.75 for 
the second and third tertiles, respectively) in Cox-regression models, after multiple adjustments. All subclasses of fla-
vonoids, but flavones and isoflavones, were inversely correlated with incident CV events, with HRs ranging from 0.42 
(flavan-3-ols) to 0.56 (anthocyanidins). Being in the third tertile of flavan-3-ols (HR = 0.68; 95% CI 0.48–0.96), antho-
cyanidins (HR = 0.66; 95% CI 0.46–0.95) and flavanones (HR = 0.59; 95% CI 0.40–0.85) was inversely associated with 
all-cause mortality. Total and subclasses of flavonoids were not significantly associated with the risk of CV mortality.
Conclusions: Flavonoid intake was inversely associated with CV risk, CV non-fatal events and all-cause mortality in a 
cohort with a low consumption of soy, tea and cocoa, which are typically viewed as the foods responsible for flavo-
noid-related benefits.
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Background
Flavonoids are a group of plant metabolites widely 
distributed in the plant kingdom with antioxidant 
properties, which can be classified into seven subgroups 
based on their chemical structure: flavanones, flavones, 
flavonols, flavan-3-ols, anthocyanidins, isoflavones and 
proanthocyanidins [1]. These compounds are present 
in small quantities in fruits, vegetables, tea, wine, nuts, 
seeds, herbs, spices, cocoa, soybean [2–4].
A wide spectrum of health benefits, such as antioxi-
dant, anti-inflammatory, antibacterial, antithrombotic, 
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anti-carcinogenetic properties have been reported for fla-
vonoids [5].
Many epidemiological studies have reported inverse 
associations between the total flavonoid intake or the 
intake of specific classes of flavonoids and the incidence 
or mortality for cardiovascular (CV) diseases [6–20]. 
However, not all studies agreed about the cardio-pro-
tective effects of these compounds [21–27]. Many stud-
ies referred to specific foods, which are the main sources 
of flavonoids in different populations, such as tea [13, 28, 
29], cocoa [28, 30], soy [17].
We have studied a population-based cohort of middle-
aged adults, coming from a semi-rural area, where the 
consumption of some flavonoid-rich foods, such as cocoa 
and soybean is almost negligible, while the most impor-
tant sources of flavonoids are fruits and red wine.
The primary objective of this study was establishing if 
the consumption of flavonoids was inversely associated 
with the CV risk evaluated after 12-year follow-up; the 
secondary aims were evaluating the associations between 
flavonoid intake and CV incidence, CV mortality, and all-
cause mortality in our cohort.
Methods
All the Caucasian patients (n = 1,877), aged 45–64 years, 
of six family physicians were invited to participate in a 
metabolic screening in 2001–2003. These subjects were 
representative of the Local Health Units of the province 
of Asti (northwestern Italy) [31]. Exclusion criteria were: 
inability to go to the office of the family physician and to 
give the informed consent.
Of these, 1,658 (88.3%) subjects gave their writ-
ten informed consent to participate and 219 patients 
declined. Both the participants and non-participants 
were similar to the resident population of a correspond-
ing age range with respect to the percentage of males, 
level of education, prevalence of known diabetes, and 
residence in a rural area [31]. The study was approved by 
the local ethics committee. All procedures conformed to 
the principles of the Helsinki Declaration.
Methods
In the morning and after fasting, weight, height, waist 
circumference, and blood pressure were measured in 
the office of the family physicians. Glucose, insulin, total 
cholesterol, HDL-cholesterol, triglyceride, uric acid and 
high-sensitivity C-reactive protein (CRP) levels were 
determined. If the serum glucose value was ≥110 mg/dl, 
a second fasting glucose determination was performed. 
Two blood pressure measurements were performed with 
mercury sphygmomanometers and the appropriate cuff 
sizes after a 10-min rest in the sitting position, and the 
values reported are the means of the two measurements. 
The waist circumference was measured by a plastic tape 
meter at the level of the umbilicus. The measurements 
were performed by trained physicians holding a grant.
Patients completed the Minnesota Leisure Time Physi-
cal Activity questionnaire [32]. The physical activity level 
was calculated as the product of the duration and fre-
quency of each activity (in hours/week), weighted by an 
estimate of the metabolic equivalent of the activity and 
summed for the activities performed.
From January to November 2014, the patients were 
submitted to a blood sample analysis and a follow-up 
visit by their family physicians. Information on the vital 
status of each patient and the causes of death of those 
who died was collected from the demographic files of the 
town of residence or death.
The laboratory methods have been described previ-
ously [31, 33]. All samples were run blindly.
Ascertainment of flavonoid intake
The semi-quantitative food-frequency questionnaire used 
in the EPIC (European Prospective Investigation into 
Cancer and Nutrition) studies was used for all subjects 
[34]. It assessed average frequency and portion intake 
of 148 foods consumed during the 12 months before the 
enrolment. For each food item, the participants had to 
mark if the food or dish was consumed or not during the 
previous year. For all food items consumed, the subjects 
should select their typical portion size with the help of 
photographs, the consumption frequency and the time 
period (day, week, month or year), which suited them 
best. Questions about the type of fat for cooking were 
also included. This tool has been previously validated 
[34]. A dietician, blinded to the study details, checked 
all questionnaires for completeness, internal coherence, 
and plausibility. In case of uncertain answers, the patients 
were interviewed by the dietician.
Each nutrient was adjusted for total energy, using the 
residual method [35]. The reliability of the reported 
energy intake was assessed by calculating the ratio of esti-
mated energy intake to predicted basal metabolic rate, 
using age- and sex-specific formulas derived by Schofield 
[36]. Subjects with a ratio <0.88 were classified as under-
reporters [37].
Dietary intake of total and subclasses of flavonoids 
were estimated by using the latest detailed food compo-
sition tables published by the US Department of Agri-
culture (USDA) on the seven major classes of flavonoids 
[2–4] and extended with information from an European 
database [38]. Merging of the databases gave a single 
data-file. Flavonoid intake was computed by multiplying 
the specific flavonoid content of the serving of each food 
item (mg aglicone equivalent/100  g food) by the daily 
consumption (g/day) of the selected food item. Estimated 
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total intake of individual flavonoids was the sum of indi-
vidual flavonoid intakes from all food sources reported 
in the questionnaire. Total flavonoid intake was calcu-
lated by summing up the seven subclasses (flavanones, 
flavones, flavonols, flavan-3-ols, anthocyanidins, isofla-
vones and proanthocyanidins), and were expressed as 
mg/day aglycones.
The contribution of each food to the total intake of sub-
group and total flavonoids was calculated as a percent-
age; single foods were then grouped into large categories.
All flavonoid subgroups that were estimated, their 
respective compounds, and the main food sources are 
shown in Table 1.
Definitions
Alcohol intake was assessed by multiplying the mean 
daily consumption of each beverage by its ethanol 
content, to give grams of alcohol/day. Moderate and 
heavy drinkers were considered in the case of consump-
tion of ≤30 and >30  g/day alcohol, respectively, in line 
with Italian guidelines [39].
Diabetes mellitus was defined according to published 
recommendations [40]. Estrogen use included both con-
traceptive medications or estrogen replacement therapy. 
The use of nutritional supplements was infrequent in this 
cohort and was limited to multivitamin, iron, calcium or, 
less frequently, magnesium.
The CV risk score was estimated with the Framingham 
risk score [41]. The diagnosis of CV disease was based 
on documented events that were recorded by the fam-
ily physician (i.e. angina, previous myocardial infarction, 
coronary artery by-pass graft or another invasive proce-
dure to treat coronary artery disease, transient ischemic 
attack, stroke, gangrene, amputation, vascular surgery, 
Table 1 Flavonoid classes and compounds, and respective dietary intakes and main food sources in the whole cohort
Sources contributing to ≥5% of the intake.
Compounds Median intake (mg/day) Sources (%)
Total flavonoids 251.0 Fruits (38)
Red wine (25)
Vegetables (5)
Tea (5)
Proanthocyanids Dimers, Trimers, 4-6mers, 7-10mers,  
polymers of flavon-3-ols or flavanols
96.1 Fruits (50)
Red wine (23)
Legumes (6)
Flavan-3-ols (−)-Epicatechin
(−)-Epicatechin 3-gallate
(−)-Epigallocatechin
(−)-Epigallocatechin 3-gallate
(+)-Catechin
(+)-Gallocatechin
Theaflavin
Theaflavin-3, 3′-digallate
Theaflavin-3′-gallate
Theaflavin-3-gallate
Thearubigins
50.4 Fruits (26)
Tea (21)
Red wine (19)
Anthocyanidins Cyanidin
Delphinidin
Malvidin
Pelargonidin
Peonidin
Petunidin
32.9 Red wine (53)
Vegetables (17)
Fruits (11)
Flavanones Eriodictyol
Hesperetin
Naringenin
24.2 Fruits (71)
Red wine (12)
Flavonols Isorhamnetin
Kaempferol
Myricetin
Quercetin
14.4 Vegetables (34)
Red wine (14)
Fruits (13)
Flavones Apigenin
Luteolin
1.2 Vegetables (51)
Red wine (18)
Fruits (8)
Isoflavones Daidzein
Genistein
Glycitein
0.7 Legumes (90)
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intermittent claudication, absent foot pulses and abnor-
mal brachial and posterior tibial blood pressure using 
Doppler techniques).
The underlying cause of death was available for all the 
deceased patients and was derived from the death cer-
tificate and coded according to the ICD-9 (International 
Classification of Diseases, Ninth Revision). Deaths due to 
CV diseases corresponded to ICD codes 410–414 (coro-
nary artery diseases), 430–438 (strokes), 440 (peripheral 
artery diseases) and other ICD codes between 390–459 
and 798.1 (other CV diseases).
Statistical analyses
Considering a type I error of 0.05 and a type II error of 
0.90, a minimum of 83 subjects were needed for each ter-
tile to detect a 10% difference in the CV scores between 
the tertiles of total flavonoid intakes.
Dietary total flavonoid intakes of the cohort were 
divided into tertiles, separately per sex. Cut-off points 
were 191.5, 401.2 and 138.3, 322.3  mg/day, respectively 
for men and women.
The distributions of flavonoid intake, fasting insulin, 
triglycerides, CRP values were skewed. The character-
istics of the cohort according to the tertiles of flavonoid 
intakes were analyzed by ANOVA, Kruskal–Wallis tests 
(for not-normally distributed variables) or the χ2 test, as 
appropriate.
A multiple regression was performed to assess the 
association between the 2014 CV score and the varia-
tions from baseline to follow-up (values at 2014 minus 
values at baseline) in the CV risk score, and the tertiles of 
flavonoid intakes, after adjusting for BMI, education (pri-
mary/secondary/university), living in a rural area, METs 
(hour/week), alcohol intake (g/day), history of CV dis-
eases, values of fasting glucose, log-CRP, fiber, and satu-
rated fatty acid intakes. We did not include age, sex, total 
and HDL-cholesterol, smoking habits and blood pressure 
values, because these variables were included in the CV 
score calculation, to avoid over-controlling. However, 
when we controlled for these variables, results were not 
significantly different.
The relationships between tertiles of flavonoid intakes 
and all-cause mortality and CV mortality and incidence 
were assessed by estimating the hazard ratio (HR) and its 
95% confidence intervals (CI) in Cox regression models, 
adjusted for age, sex, BMI, education, living in a rural 
area, METs (hour/week), alcohol, fiber, and saturated 
fatty acid intakes, smoking, values of systolic and dias-
tolic blood pressure, total and HDL-cholesterol, fasting 
glucose, CRP, statin and aspirin use.
In all these analyses, individuals in the first (lower) ter-
tile of flavonoid intakes were considered as the reference 
group, and the other groups were introduced as dummy 
variables (IBM SPSS Statistical Software Version 22).
Results
Out of 1,658 subjects, 138 (8.3%) resulted under-report-
ers. Among the tertiles of flavonoid intake, the percent-
age of under-reporters did not differ (8.2, 8.5 and 8.3% in 
the first, second and third tertiles, respectively).
Mean and median intake of total flavonoids were 320 
and 251  mg/day, respectively (Table  1).Pearson correla-
tions between flavonoids ranged from weak (r = 0.04 for 
flavan-3-ols with isoflavones) to high (r = 0.80 for flavan-
3-ols with proanthocyanids).
Descriptive characteristics of the cohort by tertiles of 
flavonoid intakes are shown in Table 2.
In the lowest tertile, there was a higher percentage of 
smokers, alcohol abstainers, less educated individu-
als, hypertensive and diabetic patients (Table 2). On the 
other hand, subjects with the highest flavonoid intake 
were more frequently heavy drinkers living in a rural 
area, were more physically active, ate more calories, fiber 
and antioxidant vitamins, and less total fat and saturated 
fat. In individuals within the lowest tertile, the metabolic 
pattern was significantly worse, CRP values increased, 
and the CV risk score higher.
The 2014 CV risk score was significantly increased in 
the individuals with the lowest intake of total flavonoids 
and their subclasses, with the exception of isoflavones 
(Table  3). Similarly, after a mean 12-year follow-up, the 
difference in the scores (2014 score minus baseline score) 
was higher in those subjects. In a multiple regression 
models, being in the third (higher) tertile of flavonoid 
intake was inversely associated with the 2014 CV score 
and with change in score values from baseline to follow-
up, after adjusting for BMI, education, living in a rural 
area, METs (hour/week), history of CV diseases, values 
of fasting glucose, log-CRP, alcohol, fiber, and saturated 
fatty acid intakes.
During follow-up, 125 incident CV events were diag-
nosed and 220 deaths occurred, 84 of which due to CV 
causes (Table 4). The incidence of CV events was signifi-
cantly lower in individuals with the higher intake of total 
flavonoids and with higher intake of all subclasses of fla-
vonoids, but flavones and isoflavones, in Cox-regression 
models after adjustments for age, sex, BMI, education, 
living in a rural area, METs (hour/week), alcohol, fiber, 
and saturated fatty acid intakes, smoking, values of sys-
tolic and diastolic blood pressure, total and HDL-cho-
lesterol, fasting glucose, CRP, statin and aspirin use. HRs 
ranged from 0.42 for the higher tertile of flavan-3-ols to 
0.56 for the higher tertile of anthocyanidins in the Cox 
model after multiple adjustments.
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Table 2 Baseline characteristics by tertiles of flavonoid intake (the first the lower; the third, the higher)
CHO carbohydrates, CRP C-reactive protein, CV cardiovascular.
*Kruskall–Wallis test for not-normally distributed variables.
First tertile Second tertile Third tertile P
Number 552 551 555
Median intake (mg/day) 89.0 251.4 532.3
Current smoking (%) 28.4 25.7 17.5 <0.001
Males (%) 47.1 46.8 47.2 0.99
Living in a rural area (%) 36.8 36.8 47.4 <0.001
Alcohol
 Alcohol abstainers (%) 54.9 41.0 35.7
 Moderate alcohol drinking (%) 31.5 41.4 38.6
 Heavy alcohol drinking (%) 13.6 17.6 25.8 <0.001
Education
 Primary school (%) 78.6 69.9 75.3
 Secondary school (%) 14.5 21.8 17.5
 University (%) 6.9 8.4 7.2 0.02
 History of hypertension (%) 56.5 47.0 50.5 0.006
 History of diabetes mellitus (%) 8.5 4.0 4.5 0.002
 History of CV disease (%) 6.5 5.3 5.1 0.52
 Estrogen use (%) 4.2 5.1 5.1 0.72
 Supplements use (%) 3.3 3.3 3.4 0.98
 Statin use (%) 3.8 3.8 4.7 0.70
 Aspirin use (%) 6.0 6.0 4.1 0.29
Mean SD Mean SD Mean SD
METS (h/week) 20.5 9.4 21.7 9.5 21.9 9.6 0.04
Age (years) 54.8 5.8 54.3 5.5 54.6 5.5 0.37
BMI (kg/m2) 27.2 5.3 26.3 4.3 26.3 4.3 <0.001
Waist circumference (cm) 92.9 13.0 90.2 12.4 90.9 13.4 0.002
Total caloric intake (kcal/day) 1,917.0 722.7 2,142.7 583.2 2,149.3 667.1 <0.001
CHO intake (% total kcal) 47.6 7.6 48.4 6.8 49.5 6.8 <0.001
Total fat intake (kcal/day) 35.6 6.1 35.2 5.9 34.7 5.7 0.03
Saturated fat (% total kcal) 12.3 3.4 12.1 2.8 11.6 3.0 0.001
Polyunsaturated fat (% total kcal) 4.3 1.3 4.3 1.6 4.3 1.4 0.95
Fiber intake (g/day) 16.5 7.3 22.4 8.3 23.3 10.2 <0.001
Beta-carotene (µg/day) 2,768.7 1,658.9 3,571.5 1,840.2 3,914.8 2,292.4 <0.001
Vitamin C (mg/day) 134.9 44.5 142.4 55.0 142.8 49.4 0.01
Vitamin E (mg/day) 8.1 3.0 8.1 2.3 8.2 2.6 0.62
Systolic blood pressure (mmHg) 135.4 16.6 132.3 15.0 133.3 16.0 0.007
Diastolic blood pressure (mmHg) 84.3 9.1 82.6 9.2 82.9 9.6 0.005
Fasting glucose (mg/dl) 109.0 38.7 102.2 24.3 103.5 26.6 <0.001
Fasting insulin 9.3 6.1 8.3 3.9 8.2 4.4 <0.001*
Total cholesterol 217.9 39.5 215.2 40.0 217.7 42.2 0.46
HDL cholesterol 57.9 12.5 60.9 13.1 62.4 14.1 <0.001
Triglycerides 149.1 82.9 131.7 99.9 137.0 92.4 <0.001*
CRP (mg/l) 3.3 7.0 2.4 4.7 2.3 5.2 <0.001*
Uric acid 3.4 1.0 3.3 1.1 3.3 1.0 0.14
CV risk score 12.6 8.3 10.6 6.8 10.5 7.1 <0.001
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Table 3 CV risk score by  tertiles of  flavonoid intake (the first the lower; the third, the higher) in  a multiple regression 
model
First tertile Second tertile Third tertile
Total flavonoids Mean SD Mean SD Mean SD P
2014 CV risk score 28.8 15.4 25.3 12.6 23.8 10.7 <0.001
Β β 95% CI P Β 95% CI P
Model 1 Reference −2.58 −4.07 −1.09 <0.001 −4.36 −5.85 −2.87 <0.001
Model 2 Reference −1.27 −2.76 0.22 0.10 −2.69 −4.22 −1.16 <0.001
Mean SD Mean SD Mean SD P
Changes in CV risk score 16.2 10.1 14.7 8.1 13.4 7.4 <0.001
Β β 95% CI P Β 95% CI P
Model 1 Reference −0.98 −1.96 0.00 0.05 −2.64 −3.62 −1.66 <0.001
Model 2 Reference −0.46 −1.50 0.58 0.38 −1.92 −2.98 −0.86 <0.001
Proanthocyanids Mean SD Mean SD Mean SD P
2014 CV risk score 28.8 15.4 25.3 12.6 23.8 10.7 <0.001
Β β 95% CI P Β 95% CI P
Model 1 Reference −2.39 −3.88 −0.90 0.002 −4.29 −5.78 −2.80 <0.001
Model 2 Reference −1.07 −2.56 0.42 0.16 −2.60 −4.13 −1.07 <0.001
Mean SD Mean SD Mean SD P
Changes in CV risk score 16.1 10.2 14.7 8.0 13.3 7.4 <0.001
Β β 95% CI P Β 95% CI P
Model 1 Reference −0.96 −1.94 0.02 0.06 −2.65 −3.65 −1.65 <0.001
Model 2 Reference −0.43 −1.47 0.61 0.41 −1.93 −2.99 −0.87 <0.001
Flavan-3-ols Mean SD Mean SD Mean SD P
2014 CV risk score 28.1 15.1 25.6 12.7 24.2 11.3 <0.001
Β β 95% CI P Β 95% CI P
Model 1 Reference −1.80 −3.29 −0.31 0.02 −3.20 −4.69 −1.71 <0.001
Model 2 Reference −0.70 −2.17 0.77 0.35 −1.92 −3.41 −0.43 0.01
Mean SD Mean SD Mean SD P
Changes in CV risk score 15.8 9.8 14.9 8.4 13.6 7.5 <0.001
Β β 95% CI P Β 95% CI P
Model 1 Reference −0.58 −1.58 0.42 0.25 −1.94 −2.94 −0.94 <0.001
Model 2 Reference −0.07 −1.09 0.95 0.89 −1.39 −2.41 −0.37 0.007
Anthocyanidins Mean SD Mean SD Mean SD P
2014 CV risk score 27.9 14.7 25.5 12.6 24.5 12.0 <0.001
Β β 95% CI P Β 95% CI P
Model 1 Reference −1.60 −3.09 −0.11 0.04 −2.73 −4.22 −1.24 <0.001
Model 2 Reference −0.81 −2.26 0.64 0.28 −1.05 −2.11 0.00 0.05
Mean SD Mean SD Mean SD P
Changes in CV risk score 15.7 9.4 14.7 8.5 13.8 8.0 0.001
Β β 95% CI P Β 95% CI P
Model 1 Reference −0.68 −1.68 0.32 0.18 −1.65 −2.65 −0.65 0.001
Model 2 Reference −0.27 −1.29 0.75 0.60 −0.90 −1.74 −0.06 0.03
Flavanones Mean SD Mean SD Mean SD P
2014 CV risk score 28.2 14.8 25.8 12.5 23.9 11.9 <0.001
Β Β 95% CI P Β 95% CI P
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Total and subclasses of flavonoids were not significantly 
associated with the risk of CV mortality in the same Cox 
model (Table 4).
Being in the third tertile of flavan-3-ols (HR  =  0.68; 
95% CI 0.48–0.96), anthocyanidins (HR  =  0.66; 95% 
CI 0.46–0.95) and flavanones (HR  =  0.59; 95% CI 
0.40–0.85) was inversely associated with all-cause 
mortality.
Data did not change after excluding the 138 under-
reporters, the 79 women on estrogen therapy, the 55 
individuals on nutritional supplements, and after adjust-
ing for antioxidant vitamin intakes.
Table 3 continued
Flavanones Mean SD Mean SD Mean SD P
Model 1 Reference −2.38 −3.87 −0.89 0.002 −3.90 −5.39 −2.41 <0.001
Model 2 Reference −1.90 −3.35 −0.45 0.01 −2.70 −4.19 −1.21 <0.001
Mean SD Mean SD Mean SD P
Changes in CV risk score 15.8 9.3 14.7 8.9 13.7 7.7 <0.001
Β Β 95% CI P Β 95% CI P
Model 1 Reference −1.13 −2.11 −0.15 0.02 −1.97 −2.95 −0.99 <0.001
Model 2 Reference −0.98 −1.98 0.02 0.06 −1.51 −2.55 −0.47 0.004
Flavonols Mean SD Mean SD Mean SD P
2014 CV risk score 27.5 15.0 25.2 12.2 25.2 12.1 0.004
Β Β 95% CI P Β 95% CI P
Model 1 Reference −2.10 −3.59 −0.61 0.006 −2.33 −3.82 −0.84 0.002
Model 2 Reference −1.13 −2.60 0.34 0.13 −1.21 −2.40 −0.02 0.04
Mean SD Mean SD Mean SD P
Changes in CV risk score 15.4 9.5 14.5 7.9 14.3 8.6 <0.001
Β Β 95% CI P Β 95% CI P
Model 1 Reference −0.84 −1.82 0.14 0.10 −1.29 −2.29 −0.29 0.01
Model 2 Reference −0.44 −1.46 0.58 0.39 −0.72 −1.78 0.34 0.18
Flavones Mean SD Mean SD Mean SD P
2014 CV risk score 28.2 15.2 25.4 12.3 24.3 11.6 <0.001
Β Β 95% CI P Β 95% CI P
Model 1 Reference −2.59 −4.08 −1.10 <0.001 −3.43 −4.92 −1.94 <0.001
Model 2 Reference −1.74 −3.21 −0.27 0.02 −2.12 −3.65 −0.59 0.007
Mean SD Mean SD Mean SD P
Changes in CV risk score 15.8 10.1 14.5 8.3 13.9 7.3 0.001
Β Β 95% CI P Β 95% CI P
Model 1 Reference −1.37 −2.37 −0.37 0.007 −1.75 −2.75 −0.75 <0.001
Model 2 Reference −1.02 −2.02 −0.02 0.04 −1.28 −2.32 −0.24 0.02
Isoflavones Mean SD Mean SD Mean SD P
2014 CV risk score 26.5 13.2 27.1 14.1 24.4 12.2 0.002
Β Β 95% CI P Β 95% CI P
Model 1 Reference 0.72 −0.77 2.21 0.34 −1.54 −3.03 −0.05 0.04
Model 2 Reference 0.97 −0.46 2.40 0.19 −0.35 −1.82 1.12 0.64
Mean SD Mean SD Mean SD P
Changes in CV risk score 14.8 8.4 15.4 9.6 14.1 7.9 0.03
Β Β 95% CI P Β 95% CI P
Model 1 Reference 0.74 −0.25 1.73 0.15 −0.45 −1.45 0.55 0.38
Model 2 Reference 0.96 −0.06 1.98 0.06 0.03 −0.99 1.05 0.96
Model 1 adjusted for BMI, education, living in a rural area, Model 2 adjusted for BMI, education, living in a rural area, METS (h/week), alcohol intake, history of CV 
diseases, values of fasting glucose, log-CRP, fiber, and saturated fatty acid intakes.
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Table 4 Cardiovascular events and  all-cause and  cardiovascular mortality by  tertiles of  flavonoid intake (the first the 
lower; the third, the higher)
First tertile Second tertile Third tertile
Total flavonoids
 Incident CV events 54 40 31
HR HR 95% CI P HR 95% CI P
  Model 1 1 0.65 0.42–0.99 0.05 0.45 0.28–0.73 0.001
  Model 2 1 0.64 0.42–1.00 0.05 0.46 0.28–0.75 0.002
 CV mortality 34 26 24
HR HR 95% CI P HR 95% CI P
  Model 1 1 0.97 0.56–1.67 0.90 0.81 0.45–1.44 0.47
  Model 2 1 0.95 0.54–1.66 0.85 0.83 0.46–1.51 0.55
 All-cause mortality 89 69 62
HR HR 95% CI P HR 95% CI P
  Model 1 1 0.86 0.62–1.21 0.38 0.73 0.51–1.04 0.08
  Model 2 1 0.90 0.65–1.26 0.52 0.78 0.55–1.13 0.19
Proanthocyanids
 Incident CV events 57 37 31
HR HR 95% CI P HR 95% CI P
  Model 1 1 0.56 0.36–0.86 0.01 0.42 0.26–0.68 <0.001
  Model 2 1 0.56 0.36–0.87 0.009 0.43 0.27–0.70 0.001
 CV mortality 34 27 23
HR HR 95% CI P HR 95% CI P
  Model 1 1 0.99 0.58–1.70 0.97 0.77 0.43–1.39 0.39
  Model 2 1 0.98 0.56–1.69 0.93 0.80 0.44–1.46 0.46
 All-cause mortality 90 70 60
HR HR 95% CI P HR 95% CI P
  Model 1 1 0.85 0.61–1.19 0.35 0.69 0.48–0.99 0.05
  Model 2 1 0.88 0.63–1.24 0.46 0.75 0.52–1.08 0.12
Flavan-3-ols
 Incident CV events 57 42 26
HR HR 95% CI P HR 95% CI P
  Model 1 1 0.69 0.46–1.05 0.08 0.40 0.25–0.65 <0.001
  Model 2 1 0.71 0.47–1.08 0.11 0.42 0.26–0.68 <0.001
 CV mortality 37 23 24
HR HR 95% CI P HR 95% CI P
  Model 1 1 0.75 0.44–1.29 0.30 0.70 0.40–1.20 0.19
  Model 2 1 0.79 0.46–1.37 0.40 0.72 0.41–1.26 0.25
 All-cause mortality 92 71 57
HR HR 95% CI P HR 95% CI P
  Model 1 1 0.84 0.61–1.15 0.27 0.63 0.44–0.89 0.009
  Model 2 1 0.86 0.62–1.19 0.36 0.68 0.48–0.96 0.03
Anthocyanidins
 Incident CV events 53 35 37
HR HR 95% CI P HR 95% CI P
  Model 1 1 0.59 0.38–0.92 0.02 0.58 0.37–0.92 0.02
  Model 2 1 0.58 0.37–0.91 0.02 0.56 0.36–0.89 0.02
 CV mortality 40 20 24
HR HR 95% CI P HR 95% CI P
  Model 1 1 0.58 0.33–1.01 0.05 0.65 0.37–1.15 0.14
  Model 2 1 0.56 0.32–0.98 0.04 0.67 0.38–1.18 0.16
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Table 4 continued
First tertile Second tertile Third tertile
 All-cause mortality 95 62 63
HR HR 95% CI P HR 95% CI P
  Model 1 1 0.69 0.50–0.96 0.03 0.66 0.47–0.94 0.02
  Model 2 1 0.66 0.47–0.94 0.02 0.66 0.46–0.95 0.02
Flavanones
 Incident CV events 54 42 29
HR HR 95% CI P HR 95% CI P
  Model 1 1 0.71 0.47–1.07 0.11 0.45 0.28–0.73 0.001
  Model 2 1 0.73 0.48–1.10 0.13 0.48 0.29–0.77 0.003
 CV mortality 39 24 21
HR HR 95% CI P HR 95% CI P
  Model 1 1 0.67 0.40–1.13 0.14 0.56 0.32–0.99 0.05
  Model 2 1 0.71 0.42–1.20 0.20 0.66 0.37–1.17 0.15
 All-cause mortality 91 80 49
HR HR 95% CI P HR 95% CI P
  Model 1 1 0.91 0.67–1.24 0.54 0.54 0.37–0.78 0.001
  Model 2 1 0.94 0.68–1.29 0.69 0.59 0.40–0.85 0.005
Flavonols
 Incident CV events 56 31 38
HR HR 95% CI P HR 95% CI P
  Model 1 1 0.49 0.31–0.76 0.002 0.53 0.34–0.83 0.006
  Model 2 1 0.51 0.32–0.80 0.003 0.53 0.34–0.83 0.005
 CV mortality 36 22 26
HR HR 95% CI P HR 95% CI P
  Model 1 1 0.63 0.36–1.09 0.10 0.68 0.39–1.19 0.18
  Model 2 1 0.69 0.40–1.20 0.19 0.72 0.41–1.27 0.26
 All-cause mortality 91 64 65
HR HR 95% CI P HR 95% CI P
  Model 1 1 0.72 0.51–1.00 0.05 0.70 0.50–0.99 0.05
  Model 2 1 0.78 0.55–1.08 0.14 0.72 0.51–1.02 0.06
Flavones
 Incident CV events 42 51 32
HR HR 95% CI P HR 95% CI P
  Model 1 1 1.13 0.74–1.72 0.56 0.68 0.41–1.10 0.11
  Model 2 1 1.14 0.75–1.75 0.54 0.66 0.40–1.09 0.10
 CV mortality 30 31 23
HR HR 95% CI P HR 95% CI P
  Model 1 1 1.08 0.64–1.82 0.77 0.87 0.48–1.56 0.63
  Model 2 1 1.10 0.65–1.87 0.72 0.83 0.45–1.52 0.55
 All-cause mortality 88 71 61
HR HR 95% CI P HR 95% CI P
  Model 1 1 0.79 0.57–1.09 0.16 0.71 0.50–1.01 0.06
  Model 2 1 0.83 0.60–1.16 0.28 0.73 0.51–1.05 0.09
Isoflavones
 Incident CV events 48 38 39
HR HR 95% CI P HR 95% CI P
  Model 1 1 0.78 0.51–1.20 0.26 0.77 0.49–1.19 0.23
  Model 2 1 0.81 0.53–1.25 0.35 0.77 0.49–1.21 0.26
 CV mortality 30 34 20
HR HR 95% CI P HR 95% CI P
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Discussion
The results of this population-based cohort study suggest 
that higher dietary intakes of flavonoids may be associ-
ated with a reduced CV risk score and a 40–50% lower 
risk of non-fatal CV events.
This is intriguing since in our cohort the consumption 
of some flavonoid-rich foods inversely associated with 
CV risk such as cocoa, soybean and tea [13, 17, 28, 29], is 
infrequent, being fruits and red wine the main sources of 
flavonoids. Epidemiological studies have suggested that a 
Mediterranean diet reduces the CV risk [42] and a high 
concentration of flavonoids has been found in fruits, veg-
etables, red wine and other elements of the Mediterra-
nean diet. However, there is inconsistent evidence on the 
role of flavonoids derived from these foods and CV risk, 
since previous studies reported either a decreased CV 
incidence and mortality with increased intake of apples, 
pears, and red wine [8, 12, 16, 24, 25], or no significant 
effect [6, 10, 21, 26, 27].
We have found both a lower CV risk score at baseline 
and at follow-up in the higher tertile of flavonoid intake. 
Intriguingly, the increase in the score from enrolment 
to the end of follow-up was higher in those individuals. 
Accordingly, the consumption of flavonoid-rich food has 
been associated with lower systolic blood pressure [15, 
43, 44], lower total cholesterol [44], higher HDL choles-
terol values [44–46].
Benefits of flavonoids on blood pressure, lipid values, 
insulin resistance, and flow-mediated dilatation seem to 
derive above all from soy, cocoa and tea, as suggested by 
systematic reviews [47, 48]. However, more recently, fla-
vonoids from fruits and vegetables have been reported 
to reduce the risk of diabetes mellitus and to improve 
microvascular reactivity and inflammatory status [49–
51]. Accordingly, although a small number of incident 
CV events occurred in our cohort, the risk of non-fatal 
CV events was significantly lower in individuals with the 
higher intake of total and all subclasses of flavonoids, 
but flavones and isoflavones, which were consumed at 
negligible concentrations in our cohort. Therefore, the 
dietary intakes of flavonoids seems relevant for healthy 
CV outcomes at relatively low concentrations, since most 
inverse associations with CV risk score and non-fatal CV 
events appeared with intermediate or low intakes of spe-
cific subclasses, suggesting that even small amounts may 
be beneficial. However, a threshold of intake is probably 
needed, under which these compounds are unlike to be 
active.
Flavonoids can inhibit or induce a large variety of 
enzyme systems, involved in pathways regulating platelet 
aggregation, inflammatory and immune responses [1, 52, 
53]. Furthermore, by their antioxidant properties, flavo-
noids may protect tissues against oxygen free radicals and 
lipid peroxidation, thus contributing to the prevention of 
atherosclerosis, chronic inflammation and cancer [1, 52, 
53]. Because of their antioxidant and chelating proper-
ties, flavonoids may inactivate reactive oxygen species 
(ROS) and counteract the oxidation of circulating LDL 
particles [52–54]. Other anti-atherogenic actions pro-
posed for these compounds are: reduction of the activ-
ity of enzymes increasing ROS production; inhibition of 
HMG-CoA reductase, cholesteryl ester transfer protein 
(CEPT), angiotensin-converting enzyme, signal trans-
ducers and activators of transcription (STAT), and glu-
cose transporters; synthesis of nitric oxide; inhibition of 
platelet activation and function; anti-angiogenetic effects; 
improvement in endothelial function, vascular fragil-
ity, cellular permeability [54–56]. The anti-inflammatory 
properties of flavonoids may be due to the inhibition of 
NF-κB activation and adhesion molecule expression; 
suppression of the activity and secretion of inflamma-
tory cells; reduction of the concentrations of CRP and 
cytokines [57, 58].
The associations with fatal events were controversial 
in our cohort. No significant association was found with 
CV mortality, probably because the number of fatal CV 
events was low. Otherwise, many flavonoid subclasses, 
such as flavan-3-ols, anthocyanidins and flavanones 
were inversely associated with all-cause mortality. Pre-
vious studies have reported a reduced total and/or CV 
Table 4 continued
First tertile Second tertile Third tertile
  Model 1 1 1.23 0.74–2.03 0.42 0.78 0.44–1.41 0.42
  Model 2 1 1.21 0.73–2.02 0.48 0.74 0.41–1.36 0.34
 All-cause mortality 95 63 62
HR HR 95% CI P HR 95% CI P
  Model 1 1 0.68 0.49–0.94 0.02 0.70 0.50–0.98 0.04
  Model 2 1 1.45 1.05–2.00 0.03 1.39 1.00–1.95 0.05
Model 1 adjusted for age, sex, BMI, education, living in a rural area, METs (h/week), fiber and saturated fatty acid intakes, Model 2 adjusted for age, sex, BMI, education, 
living in a rural area, METs (hour/week), fiber, and saturated fatty acid intakes, alcohol intake, smoking, values of systolic and diastolic blood pressure, total and HDL-
cholesterol, fasting glucose, CRP, statin and aspirin use.
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mortality with proanthocyanids [19], flavan-3-ols, [11, 
19, 25], anthocyanidins [16, 19], flavonols [13, 19], fla-
vanones [16, 18], flavones [16, 19], and isoflavones [17, 
44–47]. On the other hand, other authors reported no 
protective effects of total or specific subclasses of flavo-
noids on mortality [7, 12, 21, 22, 27].
These highly divergent results among studies might be 
due to differences in nutritional, socio-cultural and eth-
nic characteristics.
The median intakes of flavonoids are highly variable 
among studies, and values ranging from 50 to 450  mg 
have been reported in European studies [54]. In particu-
lar, the following median intakes have been described 
for Mediterranean countries: 92  mg/day in Greece [59] 
and 332.4  mg/day in Spain [60]. On the other hand, in 
non-Mediterranean countries, the median consump-
tion of flavonoids was much lower, varying from 203 mg/
day in US population [19] to 88 mg/day in Sweden, and 
13  mg/day in Finland [61]. Our values were between 
these extreme intakes, in line with other Italian data [62, 
63]. The high consumption of red wine and fruits, such 
as apples and citrus fruits, in our Italian cohort justify 
the higher intake of total flavonoids and proanthocya-
nidins with respect to other non-Mediterranean cohorts 
[19, 61]. On the other hand, the low consumption of tea, 
justified the lower intakes of flavon-3-ols (in particular 
epigallocatechin 3-gallate, epicatechin 3-gallate and epi-
gallocatechin) with respect to UK and Ireland [61], and 
the negligible use of soy explain why the intake of isofla-
vones and flavones was much lower in our cohort when 
compared with Asian studies [17].
In most studies, the higher consumption of flavonoids 
was associated with an overall healthy dietary and meta-
bolic pattern, in line with our results [8, 10–12, 16–21, 
25, 26, 49]. Our cohort indeed included individuals with 
a low level of education, differently from previous stud-
ies performed in samples where most participants had at 
least a high school education [13, 16, 17, 19, 26].
Finally, many compounds tend to be present in the same 
foods: for example, in our cohort, individuals with lower 
intakes of flavonoids, ate less fiber and antioxidant vita-
mins and more saturated fats. It is therefore difficult to 
ascertain the independent effect of dietary components 
because of multicollinearity. However, our associations 
remained significant after adjusting for these dietary fac-
tors, thus suggesting that a higher flavonoid intake might 
not merely be an indicator of a healthier lifestyle.
Limitations
The EPIC questionnaire was not originally designed to 
measure flavonoid intake, but it has been extensively 
used and validated for this purpose [60, 64, 65].
The flavonoid intake might have been underestimated 
because of the limitations of the food composition data-
bases. It should be noted that the presence of particular 
flavonoids in vegetables and fruits depends on the crop 
variety, location and type of cultivation. The adaptabil-
ity of the USDA database to the Italian diet is question-
able. The absorption and microbial transformation in 
the gut of specific subclasses of flavonoids vary consid-
erably, therefore the different flavonoid bioavailability 
could have an impact on the associations between the 
assumption of these compounds and chronic diseases. 
In general, flavonoid subclasses are present simultane-
ously in foods and establishing which of the compound 
is responsible for the potential biological effect is diffi-
cult. We relied on dietary intake from the questionnaire 
administered at one point in time; thus misclassification 
of dietary exposure might have occurred if individuals 
have changed their diets during the follow-up. Further-
more, measurement error in collecting self-reported 
dietary intake is inevitable and our observational study 
was prone to the possibility of unmeasured confounding.
However, the recent versions of the USDA database 
includes more cooked foods [2], because in culinary 
preparations important losses in flavonoid content occur, 
and is the most complete and used database in the esti-
mation of flavonoid intake. Moreover, we have referred 
also to a European database, and the USDA has been 
already used for the Italian population [62–64]. We have 
used a validated instrument and, both at baseline and at 
follow-up, the associations between flavonoid intakes and 
the CV risk score were consistent. Measurement errors 
and misclassification was likely to be random and would 
have attenuated the association found. We have took care 
to adjust for many potential confounders. Finally, we have 
studied a large population-based cohort from a localized 
region, with a high level of participation, which could 
have limited the number of potential confounders.
Conclusions
Individuals with higher intakes of flavonoids showed 
a lower CV risk after a mean 12-year follow-up, and a 
reduced risk of non-fatal CV events. If these results will 
be confirmed in larger prospective cohorts, it would be 
useful to obtain reliable markers of flavonoid intake in 
order to define the optimal doses of specific flavonoids 
for CV protection.
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